1
|
Gupta S, Dubey A, Rathore AS. Role of Charge Heterogeneity on Physical Stability of Monoclonal Antibody Biotherapeutic Products. Pharm Res 2024; 41:1443-1454. [PMID: 38951451 DOI: 10.1007/s11095-024-03730-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2023] [Accepted: 06/13/2024] [Indexed: 07/03/2024]
Abstract
PURPOSE Chemical modifications in monoclonal antibodies can change hydrophobicity, charge heterogeneity as well as conformation, which eventually can impact their physical stability. In this study, the effect of the individual charge variants on physical stability and aggregation propensity in two different buffer conditions used during downstream purification was investigated. METHODS The charge variants were separated using semi-preparative cation exchange chromatography and buffer exchanged in the two buffers with pH 6.0 and 3.8. Subsequently each variant was analysed for size heterogeneity using size exclusion chromatography and dynamic light scattering, conformational stability, colloidal stability, and aggregation behaviour under accelerated stability conditions. RESULTS Size variants in each charge variant were similar in both pH conditions when analyzed without extended storage. However, conformational stability was lower at pH 3.8 than pH 6.0. All charge variants showed similar apparent melting temperature at pH 6.0. In contrast, at pH 3.8 variants A3, A5, B2, B3 and B4 display lower Tm, suggesting reduced conformational stability. Further, A2, A3 and A5 exhibit reduced colloidal stability at pH 3.8. In general, acidic variants are more prone to aggregation than basic variants. CONCLUSION Typical industry practice today is to examine in-process intermediate stability with acidic species and basic species taken as a single category each. We suggest that perhaps stability evaluation needs to be performed at specie level as different acidic or basic species have different stability and this knowledge can be used for clever designing of the downstream process to achieve a stable product.
Collapse
Affiliation(s)
- Surbhi Gupta
- Department of Chemical Engineering, DBT Centre of Excellence for Biopharmaceutical Technology, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, 110016, India
| | - Ankita Dubey
- Department of Chemical Engineering, DBT Centre of Excellence for Biopharmaceutical Technology, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, 110016, India
| | - Anurag S Rathore
- Department of Chemical Engineering, DBT Centre of Excellence for Biopharmaceutical Technology, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, 110016, India.
| |
Collapse
|
2
|
Manning MC, Holcomb RE, Payne RW, Stillahn JM, Connolly BD, Katayama DS, Liu H, Matsuura JE, Murphy BM, Henry CS, Crommelin DJA. Stability of Protein Pharmaceuticals: Recent Advances. Pharm Res 2024; 41:1301-1367. [PMID: 38937372 DOI: 10.1007/s11095-024-03726-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2024] [Accepted: 06/03/2024] [Indexed: 06/29/2024]
Abstract
There have been significant advances in the formulation and stabilization of proteins in the liquid state over the past years since our previous review. Our mechanistic understanding of protein-excipient interactions has increased, allowing one to develop formulations in a more rational fashion. The field has moved towards more complex and challenging formulations, such as high concentration formulations to allow for subcutaneous administration and co-formulation. While much of the published work has focused on mAbs, the principles appear to apply to any therapeutic protein, although mAbs clearly have some distinctive features. In this review, we first discuss chemical degradation reactions. This is followed by a section on physical instability issues. Then, more specific topics are addressed: instability induced by interactions with interfaces, predictive methods for physical stability and interplay between chemical and physical instability. The final parts are devoted to discussions how all the above impacts (co-)formulation strategies, in particular for high protein concentration solutions.'
Collapse
Affiliation(s)
- Mark Cornell Manning
- Legacy BioDesign LLC, Johnstown, CO, USA.
- Department of Chemistry, Colorado State University, Fort Collins, CO, USA.
| | - Ryan E Holcomb
- Legacy BioDesign LLC, Johnstown, CO, USA
- Department of Chemistry, Colorado State University, Fort Collins, CO, USA
| | - Robert W Payne
- Legacy BioDesign LLC, Johnstown, CO, USA
- Department of Chemistry, Colorado State University, Fort Collins, CO, USA
| | - Joshua M Stillahn
- Legacy BioDesign LLC, Johnstown, CO, USA
- Department of Chemistry, Colorado State University, Fort Collins, CO, USA
| | | | | | | | | | | | - Charles S Henry
- Department of Chemistry, Colorado State University, Fort Collins, CO, USA
| | | |
Collapse
|
3
|
Gupta S, Schöneich C, Rathore AS. Assessment of change in the basic variants composition of trastuzumab during dilution in saline for administration. Eur J Pharm Biopharm 2024; 199:114295. [PMID: 38636881 DOI: 10.1016/j.ejpb.2024.114295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2023] [Revised: 04/01/2024] [Accepted: 04/15/2024] [Indexed: 04/20/2024]
Abstract
Postproduction handling of drug products during preparation or clinical use may affect the structure and efficacy of the drug and perhaps remain unnoticed. Since chemical modifications can impact the product's structure, stability, and biological activity, this study investigates the impact of elevated temperature and subtle shift in pH on the drug product post-dilution in saline. The mAb sample diluted in saline for administration was stressed at elevated temperature and slightly acidic pH condition. Extended stability studies were performed and monitored for size and charge heterogeneity. Size heterogeneity shows no significant changes, whereas charge heterogeneity shows an increase in basic variants and a reduction in main species. Further, basic variants were isolated and characterized to identify the type and site of chemical modification. Intact mass analysis and peptide mapping identify that the basic variants were attributed mainly to the isomerization of HC Asp102 into iso-Asp or its succinimide intermediate. Four basic variants were found to exhibit similar structural properties as the main and control samples. However, basic variants showed reduced binding affinity to HER2 receptor, while there was no significant difference in FcRn binding. The results indicate that modification in the HC Asp102, which is present in the CDR, affects antigen binding and thus can influence the potency of the drug product. Hence, with the conventional stability studies required to license the drug product, including in-use or extended stability studies to mimic the postproduction handling would be desirable.
Collapse
Affiliation(s)
- Surbhi Gupta
- Department of Chemical Engineering, Indian Institute of Technology Delhi,New Delhi 110016, India
| | | | - Anurag S Rathore
- Department of Chemical Engineering, Indian Institute of Technology Delhi,New Delhi 110016, India.
| |
Collapse
|
4
|
Chen N, Ren Y, Xing L, Liu Z, Chen L, Liu S, Zhou X. In situ Raman spectral observation of succinimide intermediates in amyloid fibrillation kinetics. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2024; 309:123867. [PMID: 38198993 DOI: 10.1016/j.saa.2024.123867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Revised: 12/28/2023] [Accepted: 01/05/2024] [Indexed: 01/12/2024]
Abstract
Succinimide intermediates play the crucial role in the nucleation process for protein amyloid fibril formation, as they can usually induce a non-native conformation in a fraction of soluble proteins to render amyloidogenicity and neurotoxicity. Thus, in situ detection of succinimide intermediates during amyloid fibrillation kinetics is of considerable importance, albeit challenging, because these succinimides are generally unstable in physiological conditions. Here, we found an in situ Raman spectral fingerprint to trace the succinimide intermediates in amyloid fibril formation, wherein the carbonyl symmetric stretching of cyclic imide in the succinimide derivative is located at ca. 1790 cm-1. Using its intensity as an indicator of succinimide intermediates, we have in situ detected and unravelled the role of succinimide intermediates during the oligomer formation from the Bz-Asp-Gly-NH2 dipeptide or the amyloid fibrillation kinetics of lysozyme with thermal/acid treatment.
Collapse
Affiliation(s)
- Ning Chen
- Department of Chemical Physics, University of Science and Technology of China, Hefei, Anhui 230026, China
| | - Yi Ren
- Key Laboratory of Tropical Biological Resources of the Ministry of Education, Department of Pharmaceutical Sciences, Hainan University, Haikou, Hainan 570228, China
| | - Lei Xing
- State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.
| | - Zhongqiang Liu
- Key Laboratory of Tropical Biological Resources of the Ministry of Education, Department of Pharmaceutical Sciences, Hainan University, Haikou, Hainan 570228, China.
| | - Lin Chen
- School of Physics and Materials Engineering, Hefei Normal University, Hefei, Anhui 230601, China
| | - Shilin Liu
- Department of Chemical Physics, University of Science and Technology of China, Hefei, Anhui 230026, China
| | - Xiaoguo Zhou
- Department of Chemical Physics, University of Science and Technology of China, Hefei, Anhui 230026, China.
| |
Collapse
|
5
|
Fukuda M, Graewert MA, Jeffries CM, Svergun DI, Yamazaki T, Koga A, Yamanaka Y. Small conformational changes in IgG1 detected as acidic charge variants by cation exchange chromatography. Anal Biochem 2023; 680:115302. [PMID: 37652129 DOI: 10.1016/j.ab.2023.115302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Revised: 08/17/2023] [Accepted: 08/28/2023] [Indexed: 09/02/2023]
Abstract
Fully characterizing the post-translational modifications present in charge variants of therapeutic monoclonal antibodies (mAbs), particularly acidic variants, is challenging and remains an open area of investigation. In this study, to test the possibility that chromatographically separated acidic fractions of therapeutic mAbs contain conformational variants, we undertook a mAb refolding approach using as a case study an IgG1 that contains many unidentified acidic peaks with few post-translational modifications, and examined whether different acidic peak fractions could be generated corresponding to these variants. The IgG1 drug substance was denatured by guanidine hydrochloride, without a reducing agent present, and gradually refolded by stepwise dialysis against arginine hydrochloride used as an aggregation suppressor. Each acidic chromatographic peak originally contained in the IgG1 drug substance was markedly increased by this stepwise refolding process, indicating that these acidic variants are conformational variants. However, no conformational changes were detected by small-angle X-ray scattering experiments for the whole IgG1, indicating that the conformational changes are minor. Chromatographic, thermal and fluorescence analyses suggested that the conformational changes are a localized denaturation effect centred around the aromatic amino acid regions. This study provides new insights into the characterization of acidic variants that are currently not fully understood.
Collapse
Affiliation(s)
- Masakazu Fukuda
- Formulation Development Department, Chugai Pharmaceutical Co., Ltd., 5-5-1 Ukima, Kita-ku, Tokyo, 115-8543, Japan; Laboratory of Functional Molecular Chemistry, Kobe Pharmaceutical University, 4-19-1, Motoyamakita-machi, Higashinada-ku, Kobe, 658-8558, Japan.
| | - Melissa A Graewert
- European Molecular Biology Laboratory (EMBL) Hamburg Unit, c/o Deutsches Elektronen Synchrotron (DESY), 22607, Hamburg, Germany
| | - Cy M Jeffries
- European Molecular Biology Laboratory (EMBL) Hamburg Unit, c/o Deutsches Elektronen Synchrotron (DESY), 22607, Hamburg, Germany
| | - Dmitri I Svergun
- European Molecular Biology Laboratory (EMBL) Hamburg Unit, c/o Deutsches Elektronen Synchrotron (DESY), 22607, Hamburg, Germany
| | - Tadao Yamazaki
- Formulation Development Department, Chugai Pharmaceutical Co., Ltd., 5-5-1 Ukima, Kita-ku, Tokyo, 115-8543, Japan
| | - Akiko Koga
- Formulation Development Department, Chugai Pharmaceutical Co., Ltd., 5-5-1 Ukima, Kita-ku, Tokyo, 115-8543, Japan
| | - Yuji Yamanaka
- Formulation Development Department, Chugai Pharmaceutical Co., Ltd., 5-5-1 Ukima, Kita-ku, Tokyo, 115-8543, Japan
| |
Collapse
|
6
|
Jin X, He B. Combination of On-Line and Off-Line Two-Dimensional Liquid Chromatography-Mass Spectrometry for Comprehensive Characterization of mAb Charge Variants and Precise Instructions for Rapid Process Development. Int J Mol Sci 2023; 24:15184. [PMID: 37894864 PMCID: PMC10607358 DOI: 10.3390/ijms242015184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Revised: 10/04/2023] [Accepted: 10/12/2023] [Indexed: 10/29/2023] Open
Abstract
Charge variants, as an important quality attribute of mAbs, must be comprehensively characterized and monitored during development. However, due to their complex structure, the characterization of charge variants is challenging, labor-intensive, and time-consuming when using traditional approaches. This work combines on-line and off-line 2D-LC-MS to comprehensively characterize mAb charge variants and quickly offer precise instructions for process development. Six charge variant peaks of mAb 1 were identified using the developed platform. Off-line 2D-LC-MS analysis at the peptide level showed that the acidic peak P1 and the basic peaks P4 and P5 were caused by the deamidation of asparagine, the oxidation of methionine, and incomplete C-terminal K loss, respectively. On-line 2D-LC-MS at the intact protein level was used to identify the root causes, and it was found that the acidic peak P2 and the basic peak P6 were due to the glutathionylation of cysteine and succinimidation of aspartic acid, respectively, which were not found in off-line 2D-LC-MS because of the loss occurring during pre-treatment. These results suggest that process development could focus on cell culture for adjustment of glutathionylation. In this paper, we propose the concept of precision process development based on on-line 2D-LC-MS, which could quickly offer useful data with only 0.6 mg mAb within 6 h for precise instructions for process development. Overall, the combination of on-line and off-line 2D-LC-MS can characterize mAb charge variants more comprehensively, precisely, and quickly than other approaches. This is a very effective platform with routine operations that provides precise instructions for process development within hours, and will help to accelerate the development of innovative therapeutics.
Collapse
Affiliation(s)
- Xiaoqing Jin
- College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China;
| | - Bingfang He
- College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China;
- School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211816, China
| |
Collapse
|
7
|
Zhen J, Lee J, Wang Y, McLaughlin L, Yang F, Li Z, Wang J. Characterization of N-Terminal Asparagine Deamidation and Clipping of a Monoclonal Antibody. Antibodies (Basel) 2023; 12:59. [PMID: 37753973 PMCID: PMC10525203 DOI: 10.3390/antib12030059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Revised: 09/07/2023] [Accepted: 09/15/2023] [Indexed: 09/28/2023] Open
Abstract
This study presents a novel degradation pathway of a human immunoglobulin G (IgG) molecule featuring a light chain N-terminal asparagine. We thoroughly characterize this pathway and investigate its charge profiles using cation exchange chromatography (CEX) and capillary isoelectric focusing (cIEF). Beyond the well-documented asparagine deamidation into isoaspartic acid, aspartic acid, and succinimide intermediate, a previously unreported clipping degradation pathway is uncovered. This newly identified clipped N-terminal IgG variant exhibits a delayed elution in CEX, categorized as a "basic variant", while retaining the same main peak isoelectric point (pI) in cIEF. The influence of temperature and pH on N-terminal asparagine stability is assessed across various stressed conditions. A notable correlation between deamidation percentage and clipped products is established, suggesting a potential hydrolytic chemical reaction underlying the clipping process. Furthermore, the impact of N-terminal asparagine modifications on potency is evaluated through ELISA binding assays, revealing minimal effects on binding affinity. Sequence alignment reveals homology to a human IgG with the germline gene from Immunoglobulin Lambda Variable 6-57 (IGLV6-57), which has implications for amyloid light-chain (AL) amyloidosis. This discovery of the N-terminal clipping degradation pathway contributes to our understanding of immunoglobulin light chain misfolding and amyloid fibril deposition under physiological conditions.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Jihong Wang
- Department of Analytical Sciences, U.S. Technical & Biologics Development, Horizon Therapeutics, Rockville, MD 20850, USA
| |
Collapse
|
8
|
VanAernum ZL, Sergi JA, Dey M, Toner T, Kilgore B, Lay-Fortenbery A, Wang Y, Bian S, Kochert BA, Bothe JR, Gao X, Richardson D, Schuessler HA. Discovery and Control of Succinimide Formation and Accumulation at Aspartic Acid Residues in The Complementarity-Determining Region of a Therapeutic Monoclonal Antibody. Pharm Res 2023; 40:1411-1423. [PMID: 36627449 DOI: 10.1007/s11095-022-03462-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Accepted: 12/12/2022] [Indexed: 01/11/2023]
Abstract
PURPOSE Succinimide formation and isomerization alter the chemical and physical properties of aspartic acid residues in a protein. Modification of aspartic acid residues within complementarity-determining regions (CDRs) of therapeutic monoclonal antibodies (mAbs) can be particularly detrimental to the efficacy of the molecule. The goal of this study was to characterize the site of succinimide accumulation in the CDR of a therapeutic mAb and understand its effects on potency. Furthermore, we aimed to mitigate succinimide accumulation through changes in formulation. METHODS Accumulation of succinimide was identified through intact and reduced LC-MS mass measurements. A low pH peptide mapping method was used for relative quantitation and localization of succinimide formation in the CDR. Statistical modeling was used to correlate levels of succinimide with basic variants and potency measurements. RESULTS Succinimide accumulation in Formulation A was accelerated when stored at elevated temperatures. A strong correlation between succinimide accumulation in the CDR, an increase in basic charge variants, and a decrease in potency was observed. Statistical modeling suggest that a combination of ion exchange chromatography and potency measurements can be used to predict succinimide levels in a given sample. Reformulation of the mAb to Formulation B mitigates succinimide accumulation even after extended storage at elevated temperatures. CONCLUSION Succinimide formation in the CDR of a therapeutic mAb can have a strong negative impact on potency of the molecule. We demonstrate that thorough characterization of the molecule by LC-MS, ion exchange chromatography, and potency measurements can facilitate changes in formulation that mitigate succinimide formation and the corresponding detrimental changes in potency.
Collapse
Affiliation(s)
- Zachary L VanAernum
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA.
| | - Joseph A Sergi
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| | - Monisha Dey
- Biostatistics and Research Decision Sciences, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| | - Timothy Toner
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| | - Bruce Kilgore
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| | - Ashley Lay-Fortenbery
- Preclinical Development, Merck & Co., Inc, 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| | - Yi Wang
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
- Biologics Process and Analytical Development, National Resilience, Inc, Waltham, MA, 02451, USA
| | - Shengjie Bian
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
- CMC Regulatory & Technical Strategy, Amicus Therapeutics Inc. Philadelphia, Philadelphia, PA, 19104, USA
| | - Brent A Kochert
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| | - Jameson R Bothe
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| | - Xinliu Gao
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| | - Douglas Richardson
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| | - Hillary A Schuessler
- Analytical Research and Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, USA
| |
Collapse
|
9
|
Designing Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review. Pharmaceutics 2023; 15:pharmaceutics15030935. [PMID: 36986796 PMCID: PMC10056213 DOI: 10.3390/pharmaceutics15030935] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Revised: 03/04/2023] [Accepted: 03/09/2023] [Indexed: 03/15/2023] Open
Abstract
Over the past few decades, there has been a tremendous increase in the utilization of therapeutic peptides. Therapeutic peptides are usually administered via the parenteral route, requiring an aqueous formulation. Unfortunately, peptides are often unstable in aqueous solutions, affecting stability and bioactivity. Although a stable and dry formulation for reconstitution might be designed, from a pharmaco-economic and practical convenience point of view, a peptide formulation in an aqueous liquid form is preferred. Designing formulation strategies that optimize peptide stability may improve bioavailability and increase therapeutic efficacy. This literature review provides an overview of various degradation pathways and formulation strategies to stabilize therapeutic peptides in aqueous solutions. First, we introduce the major peptide stability issues in liquid formulations and the degradation mechanisms. Then, we present a variety of known strategies to inhibit or slow down peptide degradation. Overall, the most practical approaches to peptide stabilization are pH optimization and selecting the appropriate type of buffer. Other practical strategies to reduce peptide degradation rates in solution are the application of co-solvency, air exclusion, viscosity enhancement, PEGylation, and using polyol excipients.
Collapse
|
10
|
Yi M, Sun J, Sun H, Wang Y, Hou S, Jiang B, Xie Y, Ji R, Xue L, Ding X, Song X, Xu A, Huang C, Quan Q, Song J. Identification and characterization of an unexpected isomerization motif in CDRH2 that affects antibody activity. MAbs 2023; 15:2215364. [PMID: 37229604 DOI: 10.1080/19420862.2023.2215364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Revised: 04/17/2023] [Accepted: 05/15/2023] [Indexed: 05/27/2023] Open
Abstract
Aspartic acid (Asp) isomerization is a spontaneous non-enzymatic post-translation modification causing a change in the structure of the protein backbone, which is commonly observed in therapeutic antibodies during manufacturing and storage. The Asps in Asp-Gly (DG), Asp-Ser (DS), and Asp-Thr (DT) motifs in the structurally flexible regions, such as complementarity-determining regions (CDRs) in antibodies, are often found to have high rate of isomerization, and they are considered "hot spots" in antibodies. In contrast, the Asp-His (DH) motif is usually considered a silent spot with low isomerization propensity. However, in monoclonal antibody mAb-a, the isomerization rate of an Asp residue, Asp55, in the aspartic acid-histidine-lysine (DHK) motif present in CDRH2 was found to be unexpectedly high. By determining the conformation of DHK motif in the crystal structure of mAb-a, we found that the Cgamma of the Asp side chain carbonyl group and the back bone amide nitrogen of successor His were in proximal contact, which facilitates the formation of succinimide intermediate, and the +2 Lys played an important role in stabilizing such conformation. The contributing roles of the His and Lys residues in DHK motif were also verified using a series of synthetic peptides. This study identified a novel Asp isomerization hot spot, DHK, and the structural-based molecular mechanism was revealed. When 20% Asp55 isomerization in this DHK motif occurred in mAb-a, antigen binding activity reduced to 54%, but the pharmacokinetics in rat was not affected significantly. Although Asp isomerization of DHK motif in CDR does not appear to have a negative impact on PK, DHK motifs in the CDRs of antibody therapeutics should be removed, considering the high propensity of isomerization and impact on antibody activity and stability.
Collapse
Affiliation(s)
- Meiqi Yi
- Department of Biologics, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Jian Sun
- Department of Biologics, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Hanzi Sun
- Department of Molecular Science, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Yifei Wang
- Department of Biologics, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Shan Hou
- Department of Biologics, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Beibei Jiang
- Department of Pharmacology, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Yuanyuan Xie
- Department of Biologics, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Ruyue Ji
- Department of Biologics, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Liu Xue
- Department of Biologics, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Xiao Ding
- Department of Translational Science, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Xiaomin Song
- Department of Pharmacology, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - April Xu
- Department of Biologics, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Chichi Huang
- Department of Biologics, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Quan Quan
- Department of Biologics, BeiGene (Beijing) Co. Ltd, Beijing, China
| | - Jing Song
- Department of Biologics, BeiGene (Beijing) Co. Ltd, Beijing, China
| |
Collapse
|
11
|
Bickel F, Griaud F, Kern W, Kroener F, Gritsch M, Dayer J, Barteau S, Denefeld B, Kao-Scharf CY, Lang M, Slupska-Muanza I, Schmidt C, Berg M, Sigg J, Boado L, Chelius D. Restoring the biological activity of crizanlizumab at physiological conditions through a pH-dependent aspartic acid isomerization reaction. MAbs 2023; 15:2151075. [PMID: 36519228 PMCID: PMC9762811 DOI: 10.1080/19420862.2022.2151075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
In this study, we report the isomerization of an aspartic acid residue in the complementarity-determining region (CDR) of crizanlizumab as a major degradation pathway. The succinimide intermediate and iso-aspartic acid degradation products were successfully isolated by ion exchange chromatography for characterization. The isomerization site was identified at a DG motif in the CDR by peptide mapping. The biological characterization of the isolated variants showed that the succinimide variant exhibited a loss in target binding and biological activity compared to the aspartic acid and iso-aspartic acid variants of the molecule. The influence of pH on this isomerization reaction was investigated using capillary zone electrophoresis. Below pH 6.3, the succinimide formation was predominant, whereas at pH values above 6.3, iso-aspartic acid was formed and the initial amounts of succinimide dropped to levels even lower than those observed in the starting material. Importantly, while the succinimide accumulated at long-term storage conditions of 2 to 8°C at pH values below 6.3, a complete hydrolysis of succinimide was observed at physiological conditions (pH 7.4, 37°C), resulting in full recovery of the biological activity. In this study, we demonstrate that the critical quality attribute succinimide with reduced potency has little or no impact on the efficacy of crizanlizumab due to the full recovery of the biological activity within a few hours under physiological conditions.
Collapse
Affiliation(s)
- Fabian Bickel
- Analytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, Switzerland
| | - François Griaud
- Analytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Wolfram Kern
- Analytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Frieder Kroener
- Analytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Manuela Gritsch
- Analytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Jérôme Dayer
- Analytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Samuel Barteau
- Analytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Blandine Denefeld
- Analytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Chi-Ya Kao-Scharf
- Analytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Manuel Lang
- Analytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Izabela Slupska-Muanza
- Analytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Carla Schmidt
- Analytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Matthias Berg
- Analytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Jürgen Sigg
- Analytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Lina Boado
- Analytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, Switzerland
| | - Dirk Chelius
- Analytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, Switzerland,CONTACT Dirk Chelius Analytical Development, Technical Research and Development Biologics, Novartis Pharma AG, Basel, Switzerland
| |
Collapse
|
12
|
Mieczkowski C, Zhang X, Lee D, Nguyen K, Lv W, Wang Y, Zhang Y, Way J, Gries JM. Blueprint for antibody biologics developability. MAbs 2023; 15:2185924. [PMID: 36880643 PMCID: PMC10012935 DOI: 10.1080/19420862.2023.2185924] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Accepted: 02/24/2023] [Indexed: 03/08/2023] Open
Abstract
Large-molecule antibody biologics have revolutionized medicine owing to their superior target specificity, pharmacokinetic and pharmacodynamic properties, safety and toxicity profiles, and amenability to versatile engineering. In this review, we focus on preclinical antibody developability, including its definition, scope, and key activities from hit to lead optimization and selection. This includes generation, computational and in silico approaches, molecular engineering, production, analytical and biophysical characterization, stability and forced degradation studies, and process and formulation assessments. More recently, it is apparent these activities not only affect lead selection and manufacturability, but ultimately correlate with clinical progression and success. Emerging developability workflows and strategies are explored as part of a blueprint for developability success that includes an overview of the four major molecular properties that affect all developability outcomes: 1) conformational, 2) chemical, 3) colloidal, and 4) other interactions. We also examine risk assessment and mitigation strategies that increase the likelihood of success for moving the right candidate into the clinic.
Collapse
Affiliation(s)
- Carl Mieczkowski
- Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA
| | - Xuejin Zhang
- Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA
| | - Dana Lee
- Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA
| | - Khanh Nguyen
- Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA
| | - Wei Lv
- Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA
| | - Yanling Wang
- Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA
| | - Yue Zhang
- Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA
| | - Jackie Way
- Department of Protein Sciences, Hengenix Biotech, Inc, Milpitas, CA, USA
| | - Jean-Michel Gries
- President, Discovery Research, Hengenix Biotech, Inc, Milpitas, CA, USA
| |
Collapse
|
13
|
Beck A, Nowak C, Meshulam D, Reynolds K, Chen D, Pacardo DB, Nicholls SB, Carven GJ, Gu Z, Fang J, Wang D, Katiyar A, Xiang T, Liu H. Risk-Based Control Strategies of Recombinant Monoclonal Antibody Charge Variants. Antibodies (Basel) 2022; 11:73. [PMID: 36412839 PMCID: PMC9703962 DOI: 10.3390/antib11040073] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 10/27/2022] [Accepted: 11/11/2022] [Indexed: 09/28/2023] Open
Abstract
Since the first approval of the anti-CD3 recombinant monoclonal antibody (mAb), muromonab-CD3, a mouse antibody for the prevention of transplant rejection, by the US Food and Drug Administration (FDA) in 1986, mAb therapeutics have become increasingly important to medical care. A wealth of information about mAbs regarding their structure, stability, post-translation modifications, and the relationship between modification and function has been reported. Yet, substantial resources are still required throughout development and commercialization to have appropriate control strategies to maintain consistent product quality, safety, and efficacy. A typical feature of mAbs is charge heterogeneity, which stems from a variety of modifications, including modifications that are common to many mAbs or unique to a specific molecule or process. Charge heterogeneity is highly sensitive to process changes and thus a good indicator of a robust process. It is a high-risk quality attribute that could potentially fail the specification and comparability required for batch disposition. Failure to meet product specifications or comparability can substantially affect clinical development timelines. To mitigate these risks, the general rule is to maintain a comparable charge profile when process changes are inevitably introduced during development and even after commercialization. Otherwise, new peaks or varied levels of acidic and basic species must be justified based on scientific knowledge and clinical experience for a specific molecule. Here, we summarize the current understanding of mAb charge variants and outline risk-based control strategies to support process development and ultimately commercialization.
Collapse
Affiliation(s)
- Alain Beck
- Centre d’Immunologie Pierre-Fabre (CIPF), 5 Avenue Napoléon III, 74160 Saint-Julien-en-Genevois, France
| | - Christine Nowak
- Protein Characterization, Alexion AstraZeneca Rare Disease, 100 College St., New Haven, CT 06510, USA
| | - Deborah Meshulam
- Technical Operations/CMC, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - Kristina Reynolds
- Technical Operations/CMC, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - David Chen
- Technical Operations/CMC, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - Dennis B. Pacardo
- Technical Operations/CMC, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - Samantha B. Nicholls
- Protein Sciences, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - Gregory J. Carven
- Research, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| | - Zhenyu Gu
- Jasper Therapeutics, Inc., 2200 Bridge Pkwy Suite 102, Redwood City, CA 94065, USA
| | - Jing Fang
- Biological Drug Discovery, Biogen, 225 Binney St., Cambridge, MA 02142, USA
| | - Dongdong Wang
- Global Biologics, Takeda Pharmaceuticals, 300 Shire Way, Lexington, MA 02421, USA
| | - Amit Katiyar
- CMC Technical Operations, Magenta Therapeutics, 100 Technology Square, Cambridge, MA 02139, USA
| | - Tao Xiang
- Downstream Process and Analytical Development, Boston Institute of Biotechnology, 225 Turnpike Rd., Southborough, MA 01772, USA
| | - Hongcheng Liu
- Technical Operations/CMC, Scholar Rock, 301 Binney Street, 3rd Floor, Cambridge, MA 02142, USA
| |
Collapse
|
14
|
Sarin D, Kumar S, Rathore AS. Multiattribute Monitoring of Charge-Based Heterogeneity of Recombinant Monoclonal Antibodies Using 2D HIC-WCX-MS. Anal Chem 2022; 94:15018-15026. [PMID: 36260865 DOI: 10.1021/acs.analchem.2c02931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Charged heterogeneity of monoclonal antibody (mAb) products is regarded as a critical quality attribute (CQA) depending on its impact on the safety and efficacy profile of the product. Hence, manufacturers are expected to perform a comprehensive characterization of the charge heterogeneity to ensure that the manufactured product meets its specifications. Further, monitoring is also expected during the product lifecycle to demonstrate consistency in product quality. However, conventional analytical methods for characterization of hydrophobic and charge variants are nonvolatile salt-based and require manual fraction collection and desalting steps before analysis through mass spectrometry can be performed. In the present study, a workflow of a two-dimensional liquid chromatography method using mass spectrometry (MS)-compatible buffers coupled with native mass spectrometry was performed to characterize hydrophobic variants in the first dimension and charge variants in the second dimension without any need for manual fractionation. This novel two-dimensional (2D) hydrophobic interaction chromatography (HIC)-weak cation-exchange chromatography (WCX)-MS workflow identified 10 variants in mAb A, out of which 2 variants are exclusive to the 2D orthogonal method. Similarly, for mAb B, a total of 11 variants are identified, including 5 variants exclusive to the 2D orthogonal workflow. When compared to stand-alone, HIC resolved only 4 variants for both mAbs and WCX resolved 7 variants for mAb A and 6 variants for mAb B. In addition, the proposed method allows direct characterization of hydrophobic/charge variant peaks through native mass spectrometry in a single-run workflow.
Collapse
Affiliation(s)
- Deepika Sarin
- Department of Chemical Engineering, IIT Delhi, Hauz Khas, New Delhi, Delhi 110016, India
| | - Sunil Kumar
- Department of Chemical Engineering, IIT Delhi, Hauz Khas, New Delhi, Delhi 110016, India
| | - Anurag S Rathore
- Department of Chemical Engineering, IIT Delhi, Hauz Khas, New Delhi, Delhi 110016, India
| |
Collapse
|
15
|
Long-term stability predictions of therapeutic monoclonal antibodies in solution using Arrhenius-based kinetics. Sci Rep 2021; 11:20534. [PMID: 34654882 PMCID: PMC8519954 DOI: 10.1038/s41598-021-99875-9] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Accepted: 10/01/2021] [Indexed: 11/08/2022] Open
Abstract
Long-term stability of monoclonal antibodies to be used as biologics is a key aspect in their development. Therefore, its possible early prediction from accelerated stability studies is of major interest, despite currently being regarded as not sufficiently robust. In this work, using a combination of accelerated stability studies (up to 6 months) and first order degradation kinetic model, we are able to predict the long-term stability (up to 3 years) of multiple monoclonal antibody formulations. More specifically, we can robustly predict the long-term stability behaviour of a protein at the intended storage condition (5 °C), based on up to six months of data obtained for multiple quality attributes from different temperatures, usually from intended (5 °C), accelerated (25 °C) and stress conditions (40 °C). We have performed stability studies and evaluated the stability data of several mAbs including IgG1, IgG2, and fusion proteins, and validated our model by overlaying the 95% prediction interval and experimental stability data from up to 36 months. We demonstrated improved robustness, speed and accuracy of kinetic long-term stability prediction as compared to classical linear extrapolation used today, which justifies long-term stability prediction and shelf-life extrapolation for some biologics such as monoclonal antibodies. This work aims to contribute towards further development and refinement of the regulatory landscape that could steer toward allowing extrapolation for biologics during the developmental phase, clinical phase, and also in marketing authorisation applications, as already established today for small molecules.
Collapse
|
16
|
Nakayoshi T, Wanita K, Kato K, Kurimoto E, Oda A. Computational analysis of nonenzymatic deamidation of asparagine residues catalysed by acetic acid. Mol Phys 2021. [DOI: 10.1080/00268976.2020.1827176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Tomoki Nakayoshi
- Graduate School of Pharmacy, Meijo University, Nagoya, Japan
- Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, Kanazawa, Japan
| | - Kota Wanita
- Graduate School of Pharmacy, Meijo University, Nagoya, Japan
| | - Koichi Kato
- Graduate School of Pharmacy, Meijo University, Nagoya, Japan
- Department of Pharmacy, Kinjo Gakuin University, Nagoya, Japan
| | - Eiji Kurimoto
- Graduate School of Pharmacy, Meijo University, Nagoya, Japan
| | - Akifumi Oda
- Graduate School of Pharmacy, Meijo University, Nagoya, Japan
- Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, Kanazawa, Japan
- Institute for Protein Research, Suita, Japan
| |
Collapse
|
17
|
Lee CH, Lou YC, Wang AHJ. DMTMM-Mediated Intramolecular Cyclization of Acidic Residues in Peptides/Proteins. ACS OMEGA 2021; 6:4708-4718. [PMID: 33644578 PMCID: PMC7905807 DOI: 10.1021/acsomega.0c05503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Accepted: 01/15/2021] [Indexed: 06/12/2023]
Abstract
The formation of succinimide in proteins has attracted considerable attention in protein aging and biopharmaceutical research. The succinimide formation occurs spontaneously in proteins and is prone to hydrolysis to yield aspartate and isoaspartate, resulting in altered protein functions. Herein, we demonstrated that the coupling reagent 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) can mediate intramolecular cyclization of aspartic acid to form succinimide efficiently in the LL37-derived short antimicrobial peptide KR12. The formation of succinimide in KR12 was confirmed by liquid chromatography tandem mass spectrometry and nuclear magnetic resonance. Moreover, the succinimide-containing KR12 displayed decreased antimicrobial activity, helicity, and serum stability in comparison with unmodified KR12. The succinimide formation usually changes the protein structure and function, and only in rare cases, it can help to maintain the protein stability. In addition to succinimide, DMTMM can also mediate intraresidue cyclization of N-terminal glutamate to form pyroglutamate. Our work thus provides a convenient and efficient method for preparation of succinimide/pyroglutamate-containing peptides, which can be used for studying their impact on peptide/protein function.
Collapse
Affiliation(s)
- Chi-Hua Lee
- Institute
of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan
| | - Yuan-Chao Lou
- Biomedical
Translation Research Center, Academia Sinica, Taipei 115, Taiwan
| | - Andrew H.-J. Wang
- Institute
of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan
| |
Collapse
|
18
|
Kuang J, Tao Y, Song Y, Chemmalil L, Mussa N, Ding J, Li ZJ. Understanding the pathway and kinetics of aspartic acid isomerization in peptide mapping methods for monoclonal antibodies. Anal Bioanal Chem 2021; 413:2113-2123. [PMID: 33543314 DOI: 10.1007/s00216-021-03176-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2020] [Revised: 12/28/2020] [Accepted: 01/13/2021] [Indexed: 11/26/2022]
Abstract
Isomerization of aspartic acid (Asp) in therapeutic proteins could lead to safety and efficacy concerns. Thus, accurate quantitation of various Asp isomerization along with kinetic understanding of the variant formations is needed to ensure optimal process development and sufficient product quality control. In this study, we first observed Asp-succinimide conversion in complementarity-determining regions (CDRs) Asp-Gly motif of a recombinant mAb through ion exchange chromatography, intact protein analysis by mass spectrometry, and LC-MS/MS. Then, we developed a specific peptide mapping method, with optimized sample digestion conditions, to accurately quantitate Asp-succinimide-isoAsp variants at peptide level without method-induced isomerization. Various kinetics of Asp-succinimide-isoAsp isomerization pathways were elucidated using 18O labeling followed by LC-MS analysis. Molecular modeling and molecular dynamic simulation provide additional insight on the kinetics of Asp-succinimide formation and stability of succinimide intermediate. Findings of this work shed light on the molecular construct and the kinetics of the formation of isoAsp and succinimide in peptides and proteins, which facilitates analytical method development, protein engineering, and late phase development for commercialization of therapeutic proteins.
Collapse
Affiliation(s)
- June Kuang
- Biologics Development Organization, Bristol-Myers Squibb Company, Devens, MA, 01434, USA
| | - Yuanqi Tao
- Biologics Development Organization, Bristol-Myers Squibb Company, Devens, MA, 01434, USA
- Analytical Science Biologics, Takeda Pharmaceutical Company, Lexington, MA, 02421, USA
| | - Yuanli Song
- Biologics Development Organization, Bristol-Myers Squibb Company, Devens, MA, 01434, USA
- Process Development & Manufacture Operations, GSK, MA, 02451, Waltham, USA
| | - Letha Chemmalil
- Biologics Development Organization, Bristol-Myers Squibb Company, Devens, MA, 01434, USA
| | - Nesredin Mussa
- Biologics Development Organization, Bristol-Myers Squibb Company, Devens, MA, 01434, USA
- Ultragenyx, CA, 94005, Brisbane, USA
| | - Julia Ding
- Biologics Development Organization, Bristol-Myers Squibb Company, Devens, MA, 01434, USA.
| | - Zheng Jian Li
- Biologics Development Organization, Bristol-Myers Squibb Company, Devens, MA, 01434, USA
| |
Collapse
|
19
|
Lenčo J, Šemlej T, Khalikova MA, Fabrik I, Švec F. Sense and Nonsense of Elevated Column Temperature in Proteomic Bottom-up LC-MS Analyses. J Proteome Res 2020; 20:420-432. [PMID: 33085896 DOI: 10.1021/acs.jproteome.0c00479] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Elevated column temperature represents a simple means for improving chromatographic separation of peptides. Here, we demonstrated the advantages of the column temperature in peptide separation using state-of-the-art columns. More importantly, we also determined how temperature can impair proteomic bottom-up analyses. We found that an elevated temperature in combination with the acidic pH of the mobile phase induced in-column peptide hydrolysis with high specificity to Asp and accelerated five modification reactions of amino acids. The positive effects of temperature dominated in the 30 min long gradients since the column operated at 90 °C provided the largest number of identified peptides and proteins. However, the adverse effects of temperature on peptide integrity in longer liquid chromatography-mass spectrometry (LC-MS) analyses required its reduction to obtain optimum results. The largest number of peptides was identified using the column maintained at 75 °C in 60 min long gradients, at 60 °C in 120 min long gradients, and at 45 °C in 240 min long gradients. Our results indicate that no universal column temperature exists for bottom-up LC-MS analyses. Quite the contrary, the temperature setting must be selected rationally to exploit the full capabilities of the state-of-the-art mass spectrometers in proteomic LC-MS analyses, with the gradient time being a critical factor.
Collapse
Affiliation(s)
- Juraj Lenčo
- Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203/8, 500 05 Hradec Králové, Czech Republic
| | - Tomáš Šemlej
- Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203/8, 500 05 Hradec Králové, Czech Republic
| | - Maria A Khalikova
- Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203/8, 500 05 Hradec Králové, Czech Republic
| | - Ivo Fabrik
- Biomedical Research Center, University Hospital Hradec Králové, Sokolská 581, 500 05 Hradec Králové, Czech Republic
| | - František Švec
- Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203/8, 500 05 Hradec Králové, Czech Republic
| |
Collapse
|
20
|
Wang D, Nowak C, Mason B, Katiyar A, Liu H. Analytical artifacts in characterization of recombinant monoclonal antibody therapeutics. J Pharm Biomed Anal 2020; 183:113131. [DOI: 10.1016/j.jpba.2020.113131] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Revised: 01/22/2020] [Accepted: 01/24/2020] [Indexed: 01/12/2023]
|
21
|
Shi RL, Xiao G, Dillon TM, Ricci MS, Bondarenko PV. Characterization of therapeutic proteins by cation exchange chromatography-mass spectrometry and top-down analysis. MAbs 2020; 12:1739825. [PMID: 32292112 PMCID: PMC7188404 DOI: 10.1080/19420862.2020.1739825] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Revised: 02/26/2020] [Accepted: 02/27/2020] [Indexed: 01/10/2023] Open
Abstract
Recently, cation exchange chromatography (CEX) using aqueous volatile buffers was directly coupled with mass spectrometry (MS) and applied for intact analysis of therapeutic proteins and antibodies. In our study, chemical modifications responsible for charge variants were identified by CEX-UV-MS for a monoclonal antibody (mAb), a bispecific antibody, and an Fc-fusion protein. We also report post-CEX column addition of organic solvent and acid followed by mixing at elevated temperatures, which unfolded proteins, increased ion intensity (sensitivity) and facilitated top-down analysis. mAb stressed by hydrogen peroxide oxidation was used as a model system, which produced additional CEX peaks. The on-line CEX-UV-MS top-down analysis produced gas-phase fragments containing one or two methionine residues. Oxidation of some methionine residues contributed to earlier (acidic), some to later (basic) eluting peaks, while oxidation of other residues did not change CEX elution. The abundance of the oxidized and non-oxidized fragment ions also allowed estimation of the oxidation percentage of different methionine residues in stressed mAb. CEX-UV-MS measurement revealed a new intact antibody proteoform at 5% that eluted as a basic peak and included paired modifications: high-mannose glycosylation and remaining C-terminal lysine residue (M5/M5 + K). This finding was confirmed by peptide mapping and on-column disulfide reduction coupled with reversed-phase liquid chromatography - top-down MS analysis of the collected basic peak. Overall, our results demonstrate the utility of the on-line method in providing site-specific structural information of charge modifications without fraction collection and laborious peptide mapping.
Collapse
Affiliation(s)
- Rachel Liuqing Shi
- Attribute Sciences, Process Development, Amgen Inc., Thousand Oaks, CA, USA
| | - Gang Xiao
- Attribute Sciences, Process Development, Amgen Inc., Thousand Oaks, CA, USA
| | - Thomas M. Dillon
- Attribute Sciences, Process Development, Amgen Inc., Thousand Oaks, CA, USA
| | - Margaret S. Ricci
- Attribute Sciences, Process Development, Amgen Inc., Thousand Oaks, CA, USA
| | | |
Collapse
|
22
|
Das TK, Narhi LO, Sreedhara A, Menzen T, Grapentin C, Chou DK, Antochshuk V, Filipe V. Stress Factors in mAb Drug Substance Production Processes: Critical Assessment of Impact on Product Quality and Control Strategy. J Pharm Sci 2020; 109:116-133. [DOI: 10.1016/j.xphs.2019.09.023] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2019] [Revised: 09/29/2019] [Accepted: 09/30/2019] [Indexed: 12/18/2022]
|
23
|
A generic method for intact and subunit level characterization of mAb charge variants by native mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1133:121814. [DOI: 10.1016/j.jchromb.2019.121814] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Revised: 09/19/2019] [Accepted: 09/23/2019] [Indexed: 01/16/2023]
|
24
|
Cao M, Xu W, Niu B, Kabundi I, Luo H, Prophet M, Chen W, Liu D, Saveliev SV, Urh M, Wang J. An Automated and Qualified Platform Method for Site-Specific Succinimide and Deamidation Quantitation Using Low-pH Peptide Mapping. J Pharm Sci 2019; 108:3540-3549. [DOI: 10.1016/j.xphs.2019.07.019] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2019] [Revised: 07/26/2019] [Accepted: 07/26/2019] [Indexed: 10/26/2022]
|
25
|
Füssl F, Criscuolo A, Cook K, Scheffler K, Bones J. Cracking Proteoform Complexity of Ovalbumin with Anion-Exchange Chromatography–High-Resolution Mass Spectrometry under Native Conditions. J Proteome Res 2019; 18:3689-3702. [DOI: 10.1021/acs.jproteome.9b00375] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Florian Füssl
- NIBRT—The National Institute for Bioprocessing Research and Training, Foster Avenue,
Mount Merrion, Blackrock, Co. Dublin A94 X099, Ireland
| | - Angela Criscuolo
- Thermo Fisher Scientific, Hanna-Kunath-Strasse 11, 28199 Bremen, Germany
| | - Ken Cook
- Thermo Fisher Scientific, Stafford House, 1 Boundary Park, Hemel Hempstead HP2 7GE, United Kingdom
| | - Kai Scheffler
- Thermo Fisher Scientific, Dornierstrasse 4, 82110 Germering, Germany
| | - Jonathan Bones
- NIBRT—The National Institute for Bioprocessing Research and Training, Foster Avenue,
Mount Merrion, Blackrock, Co. Dublin A94 X099, Ireland
- School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin 4 D04 V1W8, Ireland
| |
Collapse
|
26
|
Zhou K, Cao X, Bautista J, Chen Z, Hershey N, Ludwig R, Tao L, Zeng M, Das TK. Structure-Function Assessment and High-Throughput Quantification of Site-Specific Aspartate Isomerization in Monoclonal Antibody Using a Novel Analytical Tool Kit. J Pharm Sci 2019; 109:422-428. [PMID: 31469998 DOI: 10.1016/j.xphs.2019.08.018] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2019] [Revised: 08/14/2019] [Accepted: 08/21/2019] [Indexed: 12/13/2022]
Abstract
Isomerization of surface-exposed aspartic acid (Asp) in the complementarity-determining regions of therapeutic proteins could potentially impact their target binding affinity because of the sensitive location, and often requires complex analytical tactics to understand its effect on structure-function and stability. Inaccurate quantitation of Asp-isomerized variants, especially the succinimide intermediate, presents major challenge in understanding Asp degradation kinetics, its stability, and consequently establishing a robust control strategy. As a practical solution to this problem, a comprehensive analytical tool kit has been developed, which provides a solution to fully characterize and accurately quantify the Asp-related product variants. The toolkit offers a combination of 2 steps, an ion-exchange chromatography method to separate and enrich the isomerized variants in the folded structure for structure-function evaluation and a novel focused peptide mapping method to quantify the individual complementarity-determining region isomerization components including the unmodified Asp, succinimide, and isoaspartate. This novel procedure allowed an accurate quantification of each Asp-related variant and a comprehensive assessment of the functional impact of Asp isomerization, which ultimately helped to establish an appropriate control strategy for this critical quality attribute.
Collapse
Affiliation(s)
- Kaimeng Zhou
- Drug Product Science and Technology, Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901
| | - Xiang Cao
- Analytical Development, BioTherapeutics Development, Janssen Research & Development, LLC, 200 Great Valley Pkwy, Malvern, Pennsylvania 19355
| | - James Bautista
- Drug Product Science and Technology, Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901
| | - Zhi Chen
- Drug Product Science and Technology, Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901
| | - Neil Hershey
- Analytical Development, BioTherapeutics Development, Janssen Research & Development, LLC, 200 Great Valley Pkwy, Malvern, Pennsylvania 19355
| | - Richard Ludwig
- Biophysical and Chemical Characterization Center of Excellence, Bristol-Myers Squibb, 311 Pennington Rocky Hill Rd, Pennington, New Jersey 08534
| | - Li Tao
- Biophysical and Chemical Characterization Center of Excellence, Bristol-Myers Squibb, 311 Pennington Rocky Hill Rd, Pennington, New Jersey 08534
| | - Ming Zeng
- Drug Product Science and Technology, Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901.
| | - Tapan K Das
- Biophysical and Chemical Characterization Center of Excellence, Bristol-Myers Squibb, 311 Pennington Rocky Hill Rd, Pennington, New Jersey 08534
| |
Collapse
|
27
|
Utility of High Resolution NMR Methods to Probe the Impact of Chemical Modifications on Higher Order Structure of Monoclonal Antibodies in Relation to Antigen Binding. Pharm Res 2019; 36:130. [DOI: 10.1007/s11095-019-2652-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Accepted: 05/24/2019] [Indexed: 12/17/2022]
|
28
|
Beck A, Liu H. Macro- and Micro-Heterogeneity of Natural and Recombinant IgG Antibodies. Antibodies (Basel) 2019; 8:antib8010018. [PMID: 31544824 PMCID: PMC6640695 DOI: 10.3390/antib8010018] [Citation(s) in RCA: 66] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2018] [Revised: 01/19/2019] [Accepted: 02/13/2019] [Indexed: 12/22/2022] Open
Abstract
Recombinant monoclonal antibodies (mAbs) intended for therapeutic usage are required to be thoroughly characterized, which has promoted an extensive effort towards the understanding of the structures and heterogeneity of this major class of molecules. Batch consistency and comparability are highly relevant to the successful pharmaceutical development of mAbs and related products. Small structural modifications that contribute to molecule variants (or proteoforms) differing in size, charge or hydrophobicity have been identified. These modifications may impact (or not) the stability, pharmacokinetics, and efficacy of mAbs. The presence of the same type of modifications as found in endogenous immunoglobulin G (IgG) can substantially lower the safety risks of mAbs. The knowledge of modifications is also critical to the ranking of critical quality attributes (CQAs) of the drug and define the Quality Target Product Profile (QTPP). This review provides a summary of the current understanding of post-translational and physico-chemical modifications identified in recombinant mAbs and endogenous IgGs at physiological conditions.
Collapse
Affiliation(s)
- Alain Beck
- Biologics CMC and developability, IRPF, Center d'immunologie Pierre Fabre, St Julien-en-Genevois CEDEX, 74160 Saint-Julien en Genevois, France.
| | - Hongcheng Liu
- Anokion, 50 Hampshire Street, Suite 402, Cambridge, MA 02139, USA.
| |
Collapse
|
29
|
Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A, Nowak C, Xiang T, Dong DD, Sun J, Beck A, Liu H. Structure, heterogeneity and developability assessment of therapeutic antibodies. MAbs 2018; 11:239-264. [PMID: 30543482 DOI: 10.1080/19420862.2018.1553476] [Citation(s) in RCA: 165] [Impact Index Per Article: 27.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Increasing attention has been paid to developability assessment with the understanding that thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid delays during late-stage development. The concept of developability is based on the knowledge gained from the successful development of approximately 80 marketed antibody and Fc-fusion protein drug products and from the lessons learned from many failed development programs over the last three decades. Here, we reviewed antibody quality attributes that are critical to development and traditional and state-of-the-art analytical methods to monitor those attributes. Based on our collective experiences, a practical workflow is proposed as a best practice for developability assessment including in silico evaluation, extended characterization and forced degradation using appropriate analytical methods that allow characterization with limited material consumption and fast turnaround time.
Collapse
Affiliation(s)
- Yingda Xu
- a Protein Analytics , Adimab , Lebanon , NH , USA
| | - Dongdong Wang
- b Analytical Department , Bioanalytix, Inc ., Cambridge , MA , USA
| | - Bruce Mason
- c Product Characterization , Alexion Pharmaceuticals, Inc ., New Haven , CT , USA
| | - Tony Rossomando
- c Product Characterization , Alexion Pharmaceuticals, Inc ., New Haven , CT , USA
| | - Ning Li
- d Analytical Chemistry , Regeneron Pharmaceuticals, Inc ., Tarrytown , NY , USA
| | - Dingjiang Liu
- e Formulation Development , Regeneron Pharmaceuticals, Inc ., Tarrytown , NY , USA
| | - Jason K Cheung
- f Pharmaceutical Sciences , MRL, Merck & Co., Inc ., Kenilworth , NJ , USA
| | - Wei Xu
- g Analytical Method Development , MRL, Merck & Co., Inc ., Kenilworth , NJ , USA
| | - Smita Raghava
- h Sterile Formulation Sciences , MRL, Merck & Co., Inc ., Kenilworth , NJ , USA
| | - Amit Katiyar
- i Analytical Development , Bristol-Myers Squibb , Pennington , NJ , USA
| | - Christine Nowak
- c Product Characterization , Alexion Pharmaceuticals, Inc ., New Haven , CT , USA
| | - Tao Xiang
- j Manufacturing Sciences , Abbvie Bioresearch Center , Worcester , MA , USA
| | - Diane D Dong
- j Manufacturing Sciences , Abbvie Bioresearch Center , Worcester , MA , USA
| | - Joanne Sun
- k Product development , Innovent Biologics , Suzhou Industrial Park , China
| | - Alain Beck
- l Analytical chemistry , NBEs, Center d'immunologie Pierre Fabre , St Julien-en-Genevois Cedex , France
| | - Hongcheng Liu
- c Product Characterization , Alexion Pharmaceuticals, Inc ., New Haven , CT , USA
| |
Collapse
|
30
|
Füssl F, Trappe A, Cook K, Scheffler K, Fitzgerald O, Bones J. Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry. MAbs 2018; 11:116-128. [PMID: 30296204 PMCID: PMC6343805 DOI: 10.1080/19420862.2018.1531664] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Charge variant analysis is a widely used tool to monitor changes in product quality during the manufacturing process of monoclonal antibodies (mAbs). Although it is a powerful technique for revealing mAb heterogeneity, an unexpected outcome, for example the appearance of previously undetected isoforms, requires further, time-consuming analysis. The process of identifying these unknowns can also result in unwanted changes to the molecule that are not attributable to the manufacturing process. To overcome this, we recently reported a method combining highly selective cation exchange chromatography-based charge variant analysis with on-line mass spectrometric (MS) detection. We further explored and adapted the chromatographic buffer system to expand the application range. Moreover, we observed no salt adducts on the native protein, also supported by the optimal choice of MS parameters, resulting in increased data quality and mass accuracy. Here, we demonstrate the utility of this improved method by performing an in-depth analysis of adalimumab before and after forced degradation. By combining molecular mass and retention time information, we were able to identify multiple modifications on adalimumab, including lysine truncation, glycation, deamidation, succinimide formation, isomerisation, N-terminal aspartic acid loss or C-terminal proline amidation and fragmentation along with the N-glycan distribution of each of these identified proteoforms. Host cell protein (HCP) analysis was performed using liquid chromatography-mass spectrometry that verified the presence of the protease Cathepsin L. Based on the presence of trace HCPs with catalytic activity, it can be questioned if fragmentation is solely driven by spontaneous hydrolysis or possibly also by enzymatic degradation.
Collapse
Affiliation(s)
- Florian Füssl
- a Characterisation and Comparability Lab , NIBRT - The National Institute for Bioprocessing Research and Training , Co , Dublin , Ireland
| | - Anne Trappe
- a Characterisation and Comparability Lab , NIBRT - The National Institute for Bioprocessing Research and Training , Co , Dublin , Ireland.,b School of Biotechnology , Dublin City University , Dublin 9 , Ireland
| | - Ken Cook
- c Thermo Fisher Scientific , Hemel Hempstead , UK
| | | | - Oliver Fitzgerald
- e St. Vincent's University Hospital , Dublin 4 , Ireland.,f Conway Institute of Biomolecular and Biomedical Research , University College Dublin , Dublin 4 , Ireland
| | - Jonathan Bones
- a Characterisation and Comparability Lab , NIBRT - The National Institute for Bioprocessing Research and Training , Co , Dublin , Ireland.,g School of Chemical and Bioprocess Engineering, University College Dublin , Dublin 4 , Ireland
| |
Collapse
|
31
|
Sankaran PK, Kabadi PG, Honnappa CG, Subbarao M, Pai HV, Adhikary L, Palanivelu DV. Identification and quantification of product-related quality attributes in bio-therapeutic monoclonal antibody via a simple, and robust cation-exchange HPLC method compatible with direct online detection of UV and native ESI-QTOF-MS analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2018; 1102-1103:83-95. [PMID: 30380467 DOI: 10.1016/j.jchromb.2018.10.019] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Revised: 10/14/2018] [Accepted: 10/19/2018] [Indexed: 02/03/2023]
Abstract
Modern analytical ion-exchange chromatography is one of the conventional tools used for assessment of product-related quality attributes in bio-therapeutic monoclonal antibodies (mAbs). Here, we present an approach to resolve, identify, and quantify product-related substances of therapeutic mAb at its intact molecular level by cation exchange (CIEX) HPLC coupled directly to electrospray ionization - quadrupole time of flight mass spectrometry (ESI-QTOF-MS). This method utilizes pH gradient elution mode comprised of ammonium formate buffer components, and a weak cation exchange column as stationary phase. Furthermore, ion-mobility mass spectrometry (IM-MS) provided additional insights on its higher order structure. Also, orthogonal assays such as conventional CIEX-HPLC, high resolution capillary isoelectric focusing, peptide mapping, spectroscopic, and fluorescence methods were used considerably to support the findings. Additionally, an in vitro assay was included to assess the associated impact on Fc mediated function. Overall, the developed method with simultaneous detection of UV peak area percentage at 280 nm and native ESI-MS is found to be a rapid and robust analytical tool for direct assessment of structural and purity attributes, process optimization, product development, and to decipher the relevant role of micro-variants on quality, stability, and clinical outcomes.
Collapse
Affiliation(s)
- Praveen Kallamvalliillam Sankaran
- Molecular Characterization Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore 560099, India.
| | - Pradeep G Kabadi
- Molecular Characterization Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore 560099, India
| | - Chethan Gejjalagere Honnappa
- Molecular Characterization Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore 560099, India
| | - Malini Subbarao
- Bioassay Development Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore 560099, India
| | - Harish V Pai
- Bioassay Development Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore 560099, India
| | - Laxmi Adhikary
- Molecular Characterization Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore 560099, India
| | - Dinesh V Palanivelu
- Molecular Characterization Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore 560099, India
| |
Collapse
|
32
|
Yan Q, Huang M, Lewis MJ, Hu P. Structure Based Prediction of Asparagine Deamidation Propensity in Monoclonal Antibodies. MAbs 2018; 10:901-912. [PMID: 29958069 PMCID: PMC6152450 DOI: 10.1080/19420862.2018.1478646] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Identification of asparagine (Asn) sites that are prone to deamidation is critical for the development of therapeutic monoclonal antibodies (mAbs). Despite a common chemical degradation pathway, the rates of Asn deamidation can vary dramatically among different sites, and prediction of the sensitive deamidation sites is still challenging. In this study, characterization of Asn deamidation for five IgG1 and five IgG4 mAbs under both normal and stressed conditions revealed dramatic differences in the Asn deamidation rates. A comprehensive analysis of the deamidation sites indicated that the deamidation rate differences could be explained by differences in the local structure conformation, structure flexibility and solvent accessibility. A decision tree was developed to predict the deamidation propensity for all Asn sites in IgG mAbs based on the analysis of these three structural parameters. This decision tree will allow potential Asn deamidation hot spots to be identified early in development.
Collapse
Affiliation(s)
- Qingrong Yan
- a Large Molecule Analytical Development, Pharmaceutical Development and Manufacturing Sciences , Janssen R&D, LLC , Malvern , PA , USA
| | - Maggie Huang
- a Large Molecule Analytical Development, Pharmaceutical Development and Manufacturing Sciences , Janssen R&D, LLC , Malvern , PA , USA
| | - Michael J Lewis
- a Large Molecule Analytical Development, Pharmaceutical Development and Manufacturing Sciences , Janssen R&D, LLC , Malvern , PA , USA
| | - Ping Hu
- a Large Molecule Analytical Development, Pharmaceutical Development and Manufacturing Sciences , Janssen R&D, LLC , Malvern , PA , USA
| |
Collapse
|
33
|
King C, Patel R, Ponniah G, Nowak C, Neill A, Gu Z, Liu H. Characterization of recombinant monoclonal antibody variants detected by hydrophobic interaction chromatography and imaged capillary isoelectric focusing electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci 2018; 1085:96-103. [PMID: 29649755 DOI: 10.1016/j.jchromb.2018.03.049] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2018] [Revised: 03/27/2018] [Accepted: 03/30/2018] [Indexed: 12/21/2022]
Abstract
In-depth characterization of the commonly observed variants is critical to the successful development of recombinant monoclonal antibody therapeutics. Multiple peaks of a recombinant monoclonal antibody were observed when analyzed by hydrophobic interaction chromatography and imaged capillary isoelectric focusing. The potential modification causing the heterogeneity was localized to F(ab')2 region by analyzing the antibody after IdeS digestion using hydrophobic interaction chromatography. LC-MS analysis identified asparagine deamidation as the root cause of the observed multiple variants. While the isoelectric focusing method is expected to separate deamidated species, the similar profile observed in hydrophobic interaction chromatography indicates that the single site deamidation caused differences in hydrophobicity. Forced degradation demonstrated that the susceptible asparagine residue is highly exposed, which is expected as it is located in the light chain complementarity determining region. Deamidation of this single site decreased the mAb binding affinity to its specific antigen.
Collapse
Affiliation(s)
- Cory King
- Product Characterization, Alexion Pharmaceuticals, 100 College Street, New Haven CT 06510, United States
| | - Rekha Patel
- Product Characterization, Alexion Pharmaceuticals, 100 College Street, New Haven CT 06510, United States
| | - Gomathinayagam Ponniah
- Product Characterization, Alexion Pharmaceuticals, 100 College Street, New Haven CT 06510, United States
| | - Christine Nowak
- Product Characterization, Alexion Pharmaceuticals, 100 College Street, New Haven CT 06510, United States
| | - Alyssa Neill
- Product Characterization, Alexion Pharmaceuticals, 100 College Street, New Haven CT 06510, United States
| | - Zhenyu Gu
- Product Characterization, Alexion Pharmaceuticals, 100 College Street, New Haven CT 06510, United States
| | - Hongcheng Liu
- Product Characterization, Alexion Pharmaceuticals, 100 College Street, New Haven CT 06510, United States.
| |
Collapse
|
34
|
Chung S, Tian J, Tan Z, Chen J, Lee J, Borys M, Li ZJ. Industrial bioprocessing perspectives on managing therapeutic protein charge variant profiles. Biotechnol Bioeng 2018. [DOI: 10.1002/bit.26587] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Stanley Chung
- Department of Chemical Engineering; Northeastern University; Boston Massachusetts
| | - Jun Tian
- Biologics Development, Global Product Development and Supply; Bristol-Myers Squibb Company; Devens Massachusetts
| | - Zhijun Tan
- Biologics Development, Global Product Development and Supply; Bristol-Myers Squibb Company; Devens Massachusetts
| | - Jie Chen
- Biologics Development, Global Product Development and Supply; Bristol-Myers Squibb Company; Devens Massachusetts
| | - Jongchan Lee
- Biologics Development, Global Product Development and Supply; Bristol-Myers Squibb Company; Devens Massachusetts
| | - Michael Borys
- Biologics Development, Global Product Development and Supply; Bristol-Myers Squibb Company; Devens Massachusetts
| | - Zheng Jian Li
- Biologics Development, Global Product Development and Supply; Bristol-Myers Squibb Company; Devens Massachusetts
| |
Collapse
|
35
|
Ambrogelly A, Gozo S, Katiyar A, Dellatore S, Kune Y, Bhat R, Sun J, Li N, Wang D, Nowak C, Neill A, Ponniah G, King C, Mason B, Beck A, Liu H. Analytical comparability study of recombinant monoclonal antibody therapeutics. MAbs 2018; 10:513-538. [PMID: 29513619 PMCID: PMC5973765 DOI: 10.1080/19420862.2018.1438797] [Citation(s) in RCA: 57] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2017] [Revised: 01/30/2018] [Accepted: 02/05/2018] [Indexed: 10/17/2022] Open
Abstract
Process changes are inevitable in the life cycle of recombinant monoclonal antibody therapeutics. Products made using pre- and post-change processes are required to be comparable as demonstrated by comparability studies to qualify for continuous development and commercial supply. Establishment of comparability is a systematic process of gathering and evaluating data based on scientific understanding and clinical experience of the relationship between product quality attributes and their impact on safety and efficacy. This review summarizes the current understanding of various modifications of recombinant monoclonal antibodies. It further outlines the critical steps in designing and executing successful comparability studies to support process changes at different stages of a product's lifecycle.
Collapse
Affiliation(s)
- Alexandre Ambrogelly
- Biologics Analytical Operations, Pharmaceutical & Biologics Development, Gilead Sciences, Ocean Ranch Blvd, Oceanside, CA
| | - Stephen Gozo
- Analytical Research & Development-Biologics, Celgene Corporation, Morris Avenue, Summit, NJ
| | - Amit Katiyar
- Analytical Development, Bristol-Myers Squibb, Pennington Rocky Road, Pennington, NJ
| | - Shara Dellatore
- Biologics & Vaccines Bioanalytics, MRL, Merck & Co., Inc., Galloping Hill Road, Kenilworth, NJ USA
| | - Yune Kune
- Fortress Biologicals, Sawyer Road, Suite, Waltham, MA
| | - Ram Bhat
- Millennium Research laboratories, New Boston Street, Woburn, MA
| | - Joanne Sun
- Product Development, Innovent Biologics, Dongping Street, Suzhou Industrial Park, China
| | - Ning Li
- Analytical Chemistry, Regeneron Pharmaceuticals, Inc., Old Saw Mill River Road, Tarrytown, NY
| | - Dongdong Wang
- Analytical Department, BioAnalytix, Inc., Memorial Drive, Cambridge, MA
| | - Christine Nowak
- Product Characterization, Alexion Pharmaceuticals, College Street, New Haven, CT
| | - Alyssa Neill
- Product Characterization, Alexion Pharmaceuticals, College Street, New Haven, CT
| | | | - Cory King
- Product Characterization, Alexion Pharmaceuticals, College Street, New Haven, CT
| | - Bruce Mason
- Pre-formulation, Alexion Pharmaceuticals, College Street, New Haven, CT
| | - Alain Beck
- Analytical Chemistry, NBEs, Center d'Immunologie Pierre Fabre, St Julien-en-Genevois Cedex, France
| | - Hongcheng Liu
- Product Characterization, Alexion Pharmaceuticals, College Street, New Haven, CT
| |
Collapse
|
36
|
Human Fc receptor-like 5 distinguishes IgG2 disulfide isoforms and deamidated charge variants. Mol Immunol 2017; 92:161-168. [DOI: 10.1016/j.molimm.2017.10.020] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Revised: 10/17/2017] [Accepted: 10/25/2017] [Indexed: 12/16/2022]
|
37
|
Nowak C, K Cheung J, M Dellatore S, Katiyar A, Bhat R, Sun J, Ponniah G, Neill A, Mason B, Beck A, Liu H. Forced degradation of recombinant monoclonal antibodies: A practical guide. MAbs 2017; 9:1217-1230. [PMID: 28853987 DOI: 10.1080/19420862.2017.1368602] [Citation(s) in RCA: 151] [Impact Index Per Article: 21.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
Forced degradation studies have become integral to the development of recombinant monoclonal antibody therapeutics by serving a variety of objectives from early stage manufacturability evaluation to supporting comparability assessments both pre- and post- marketing approval. This review summarizes the regulatory guidance scattered throughout different documents to highlight the expectations from various agencies such as the Food and Drug Administration and European Medicines Agency. The various purposes for forced degradation studies, commonly used conditions and the major degradation pathways under each condition are also discussed.
Collapse
Affiliation(s)
- Christine Nowak
- a Product Characterization, Alexion Pharmaceuticals , New Haven , CT , USA
| | - Jason K Cheung
- b Sterile Formulation Sciences, MRL , Merck & Co., Inc. , Kenilworth , NJ, USA , USA
| | - Shara M Dellatore
- c Biologics and Vaccines Bioanalytics, MRL , Merck & Co., Inc. , Kenilworth , NJ , USA
| | - Amit Katiyar
- d Analytical Development, Bristol-Myers Squibb , Pennington , NJ , USA
| | - Ram Bhat
- e Millennium Research laboratories , Woburn , MA , USA
| | - Joanne Sun
- f Product Development, Innovent Biologics , Suzhou Industrial Park, China
| | | | - Alyssa Neill
- a Product Characterization, Alexion Pharmaceuticals , New Haven , CT , USA
| | - Bruce Mason
- a Product Characterization, Alexion Pharmaceuticals , New Haven , CT , USA
| | - Alain Beck
- g Analytical Chemistry, NBEs, Center d'Immunology Pierre Fabre , Cedex , France
| | - Hongcheng Liu
- a Product Characterization, Alexion Pharmaceuticals , New Haven , CT , USA
| |
Collapse
|
38
|
Nowak C, Ponniah G, Neill A, Liu H. Characterization of succinimide stability during trypsin digestion for LC-MS analysis. Anal Biochem 2017; 526:1-8. [PMID: 28274724 DOI: 10.1016/j.ab.2017.03.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2016] [Revised: 03/02/2017] [Accepted: 03/03/2017] [Indexed: 12/13/2022]
Abstract
LC-MS peptide mapping is the most commonly used method to analyze protein modifications. The proteins are generally digested using trypsin at a slightly basic pH at 37 °C from several hours to overnight. Assay-induced artifacts can be generated during this procedure, potentially causing false-positive or false-negative results for a given modification. Unfortunately, for the analysis of succinimide, both false-negative and false-positive results can be generated within the same procedure. This study evaluates the stability of succinimide during the peptide mapping procedure and has demonstrated that up to 13% of pre-existing succinimide was lost during a 4 h trypsin digestion at pH 5.0 which was previously determined to be optimal for the detection of succinimide. The same procedure was able to simultaneously generate approximately 3% succinimide. Using the optimized procedure, it was also found that two aspartate residues that are followed by glycine residues in the conserved Fc region of a recombinant monoclonal antibody were not prone to isomerization. On the other hand, an aspartate residue followed by a glycine in the heavy chain variable domain was highly susceptible to isomerization. Interestingly, the antibody containing the succinimide eluted from an SEC column after the monomer peak.
Collapse
Affiliation(s)
- Christine Nowak
- Product Characterization, Alexion Pharmaceuticals, 100 College Street, New Haven, CT 06510, United States
| | - Gomathinayagam Ponniah
- Product Characterization, Alexion Pharmaceuticals, 100 College Street, New Haven, CT 06510, United States
| | - Alyssa Neill
- Product Characterization, Alexion Pharmaceuticals, 100 College Street, New Haven, CT 06510, United States
| | - Hongcheng Liu
- Product Characterization, Alexion Pharmaceuticals, 100 College Street, New Haven, CT 06510, United States.
| |
Collapse
|
39
|
Ponniah G, Nowak C, Neill A, Liu H. Characterization of charge variants of a monoclonal antibody using weak anion exchange chromatography at subunit levels. Anal Biochem 2017; 520:49-57. [DOI: 10.1016/j.ab.2016.12.017] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2016] [Revised: 12/14/2016] [Accepted: 12/19/2016] [Indexed: 11/28/2022]
|
40
|
Wu LC, Chen F, Lee SL, Raw A, Yu LX. Building parity between brand and generic peptide products: Regulatory and scientific considerations for quality of synthetic peptides. Int J Pharm 2017; 518:320-334. [DOI: 10.1016/j.ijpharm.2016.12.051] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2016] [Revised: 12/12/2016] [Accepted: 12/22/2016] [Indexed: 02/06/2023]
|
41
|
Patel CN, Bauer SP, Davies J, Durbin JD, Shiyanova TL, Zhang K, Tang JX. N+1 Engineering of an Aspartate Isomerization Hotspot in the Complementarity-Determining Region of a Monoclonal Antibody. J Pharm Sci 2016; 105:512-518. [PMID: 26869414 DOI: 10.1016/s0022-3549(15)00185-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2015] [Revised: 10/30/2015] [Accepted: 11/03/2015] [Indexed: 01/22/2023]
Abstract
Aspartate (Asp) isomerization is a common degradation pathway and a potential critical quality attribute that needs to be well characterized during the optimization and development of therapeutic antibodies. A putative Asp-serine (Ser) isomerization motif was identified in the complementarity-determining region of a humanized monoclonal antibody and shown to be a developability risk using accelerated stability analyses. To address this issue, we explored different antibody engineering strategies. Direct engineering of the Asp residue resulted in a greater than 5× loss of antigen-binding affinity and bioactivity, indicating a critical role for this residue. In contrast, rational engineering of the Ser residue at the n+1 position had a negligible impact on antigen binding affinity and bioactivity compared with the parent molecule. Furthermore, the n+1 engineering strategy effectively eliminated Asp isomerization as determined by accelerated stability analysis. This outcome affirms that the rate of Asp isomerization is strongly dependent on the identity of the n+1 residue. This report highlights a systematic antibody engineering strategy for mitigating an Asp isomerization developability risk during lead optimization.
Collapse
Affiliation(s)
- Chetan N Patel
- Lilly Research Laboratories, Biotechnology Discovery Research, Eli Lilly and Company, Indianapolis, Indiana 46285.
| | - Scott P Bauer
- Lilly Research Laboratories, Biotechnology Discovery Research, Eli Lilly and Company, Indianapolis, Indiana 46285
| | - Julian Davies
- Lilly Biotechnology Center, Biotechnology Discovery Research, Eli Lilly and Company, San Diego, California 92121
| | - Jim D Durbin
- Lilly Research Laboratories, Biotechnology Discovery Research, Eli Lilly and Company, Indianapolis, Indiana 46285
| | - Tatiyana L Shiyanova
- Lilly Research Laboratories, Biotechnology Discovery Research, Eli Lilly and Company, Indianapolis, Indiana 46285
| | - Kai Zhang
- Lilly Biotechnology Center, Biotechnology Discovery Research, Eli Lilly and Company, San Diego, California 92121
| | - Jason X Tang
- Lilly Research Laboratories, Biotechnology Discovery Research, Eli Lilly and Company, Indianapolis, Indiana 46285
| |
Collapse
|
42
|
Kabadi PG, Sankaran PK, Palanivelu DV, Adhikary L, Khedkar A, Chatterjee A. Mass Spectrometry Based Mechanistic Insights into Formation of Tris Conjugates: Implications on Protein Biopharmaceutics. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2016; 27:1677-1685. [PMID: 27488315 DOI: 10.1007/s13361-016-1447-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/12/2016] [Revised: 06/23/2016] [Accepted: 07/05/2016] [Indexed: 06/06/2023]
Abstract
We present here extensive mass spectrometric studies on the formation of a Tris conjugate with a therapeutic monoclonal antibody. The results not only demonstrate the reactive nature of the Tris molecule but also the sequence and reaction conditions that trigger this reactivity. The results corroborate the fact that proteins are, in general, prone to conjugation and/or adduct formation reactions and any modification due to this essentially leads to formation of impurities in a protein sample. Further, the results demonstrate that the conjugation reaction happens via a succinimide intermediate and has sequence specificity. Additionally, the data presented in this study also shows that the Tris formation is produced in-solution and is not an in-source phenomenon. We believe that the facts given here will open further avenues on exploration of Tris as a conjugating agent as well as ensure that the use of Tris or any ionic buffer in the process of producing a biopharmaceutical drug is monitored closely for the presence of such conjugate formation. Graphical Abstract ᅟ.
Collapse
Affiliation(s)
- Pradeep G Kabadi
- Molecular Characterization Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore, 560099, India
| | - Praveen Kallamvalliillam Sankaran
- Molecular Characterization Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore, 560099, India
| | - Dinesh V Palanivelu
- Molecular Characterization Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore, 560099, India
| | - Laxmi Adhikary
- Molecular Characterization Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore, 560099, India
| | - Anand Khedkar
- Molecular Characterization Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore, 560099, India
| | - Amarnath Chatterjee
- Molecular Characterization Laboratory, Biocon Research Limited, Biocon Limited, Biocon Park, Bommasandra - Jigani Link Road, Bommasandra Industrial Area Phase IV, Bangalore, 560099, India.
| |
Collapse
|
43
|
Kumar S, Prakash S, Gupta K, Dongre A, Balaram P, Balaram H. Unexpected functional implication of a stable succinimide in the structural stability of Methanocaldococcus jannaschii glutaminase. Nat Commun 2016; 7:12798. [PMID: 27677693 PMCID: PMC5052720 DOI: 10.1038/ncomms12798] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Accepted: 08/01/2016] [Indexed: 11/16/2022] Open
Abstract
Protein ageing is often mediated by the formation of succinimide intermediates. These short-lived intermediates derive from asparaginyl deamidation and aspartyl dehydration and are rapidly converted into β-aspartyl or D-aspartyl residues. Here we report the presence of a highly stable succinimide intermediate in the glutaminase subunit of GMP synthetase from the hyperthermophile Methanocaldoccocus jannaschii. By comparing the biophysical properties of the wild-type protein and of several mutants, we show that the presence of succinimide increases the structural stability of the glutaminase subunit. The protein bearing this modification in fact remains folded at 100 °C and in 8 M guanidinium chloride. Mutation of the residue following the reactive asparagine provides insight into the factors that contribute to the hydrolytic stability of the succinimide. Our findings suggest that sequences that stabilize succinimides from hydrolysis may be evolutionarily selected to confer extreme thermal stability. Succinimide is a post-translational modification susceptible to rapid hydrolysis and generally associated with protein destabilisation. Here, the authors use mass spectroscopy to identify a stable succinimide intermediate that is responsible for the high thermostability of a thermophilic enzyme.
Collapse
Affiliation(s)
- Sanjeev Kumar
- Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064, India
| | - Sunita Prakash
- Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560012, India
| | - Kallol Gupta
- Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560012, India
| | - Aparna Dongre
- Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064, India
| | - Padmanabhan Balaram
- Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560012, India
| | - Hemalatha Balaram
- Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064, India
| |
Collapse
|
44
|
Singh SK, Narula G, Rathore AS. Should charge variants of monoclonal antibody therapeutics be considered critical quality attributes? Electrophoresis 2016; 37:2338-46. [DOI: 10.1002/elps.201600078] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2016] [Revised: 06/01/2016] [Accepted: 06/18/2016] [Indexed: 12/21/2022]
Affiliation(s)
- Sumit Kumar Singh
- Department of Chemical Engineering; Indian Institute of Technology Delhi; Hauz Khas New Delhi India
| | - Gunjan Narula
- Department of Chemical Engineering; Indian Institute of Technology Delhi; Hauz Khas New Delhi India
| | - Anurag S. Rathore
- Department of Chemical Engineering; Indian Institute of Technology Delhi; Hauz Khas New Delhi India
| |
Collapse
|
45
|
Yan Y, Wei H, Fu Y, Jusuf S, Zeng M, Ludwig R, Krystek SR, Chen G, Tao L, Das TK. Isomerization and Oxidation in the Complementarity-Determining Regions of a Monoclonal Antibody: A Study of the Modification–Structure–Function Correlations by Hydrogen–Deuterium Exchange Mass Spectrometry. Anal Chem 2016; 88:2041-50. [DOI: 10.1021/acs.analchem.5b02800] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Affiliation(s)
- Yuetian Yan
- Biologics
Development, Bristol-Myers Squibb, 311 Pennington Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Hui Wei
- Biologics
Development, Bristol-Myers Squibb, 311 Pennington Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Ya Fu
- Biologics
Development, Bristol-Myers Squibb, 311 Pennington Rocky Hill Road, Pennington, New Jersey 08534, United States
| | | | - Ming Zeng
- Biologics
Development, Bristol-Myers Squibb, 311 Pennington Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Richard Ludwig
- Biologics
Development, Bristol-Myers Squibb, 311 Pennington Rocky Hill Road, Pennington, New Jersey 08534, United States
| | | | | | - Li Tao
- Biologics
Development, Bristol-Myers Squibb, 311 Pennington Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Tapan K. Das
- Biologics
Development, Bristol-Myers Squibb, 311 Pennington Rocky Hill Road, Pennington, New Jersey 08534, United States
| |
Collapse
|
46
|
Ponniah G, Kita A, Nowak C, Neill A, Kori Y, Rajendran S, Liu H. Characterization of the Acidic Species of a Monoclonal Antibody Using Weak Cation Exchange Chromatography and LC-MS. Anal Chem 2015. [DOI: 10.1021/acs.analchem.5b02385] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Gomathinayagam Ponniah
- Product
Characterization and ‡Biochemical Process Development, Alexion Pharmaceuticals Inc., 352 Knotter Drive, Cheshire, Connecticut, 06410, United States
| | - Adriana Kita
- Product
Characterization and ‡Biochemical Process Development, Alexion Pharmaceuticals Inc., 352 Knotter Drive, Cheshire, Connecticut, 06410, United States
| | - Christine Nowak
- Product
Characterization and ‡Biochemical Process Development, Alexion Pharmaceuticals Inc., 352 Knotter Drive, Cheshire, Connecticut, 06410, United States
| | - Alyssa Neill
- Product
Characterization and ‡Biochemical Process Development, Alexion Pharmaceuticals Inc., 352 Knotter Drive, Cheshire, Connecticut, 06410, United States
| | - Yekaterina Kori
- Product
Characterization and ‡Biochemical Process Development, Alexion Pharmaceuticals Inc., 352 Knotter Drive, Cheshire, Connecticut, 06410, United States
| | - Saravanamoorthy Rajendran
- Product
Characterization and ‡Biochemical Process Development, Alexion Pharmaceuticals Inc., 352 Knotter Drive, Cheshire, Connecticut, 06410, United States
| | - Hongcheng Liu
- Product
Characterization and ‡Biochemical Process Development, Alexion Pharmaceuticals Inc., 352 Knotter Drive, Cheshire, Connecticut, 06410, United States
| |
Collapse
|
47
|
Jarasch A, Koll H, Regula JT, Bader M, Papadimitriou A, Kettenberger H. Developability Assessment During the Selection of Novel Therapeutic Antibodies. J Pharm Sci 2015; 104:1885-1898. [DOI: 10.1002/jps.24430] [Citation(s) in RCA: 149] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2014] [Revised: 02/28/2015] [Accepted: 03/03/2015] [Indexed: 01/02/2023]
|
48
|
Neill A, Nowak C, Patel R, Ponniah G, Gonzalez N, Miano D, Liu H. Characterization of Recombinant Monoclonal Antibody Charge Variants Using OFFGEL Fractionation, Weak Anion Exchange Chromatography, and Mass Spectrometry. Anal Chem 2015; 87:6204-11. [DOI: 10.1021/acs.analchem.5b01452] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
- Alyssa Neill
- Product Characterization, Alexion Pharmaceuticals Inc, 352 Knotter Drive, Cheshire, Connecticut 06410, United States
| | - Christine Nowak
- Product Characterization, Alexion Pharmaceuticals Inc, 352 Knotter Drive, Cheshire, Connecticut 06410, United States
| | - Rekha Patel
- Product Characterization, Alexion Pharmaceuticals Inc, 352 Knotter Drive, Cheshire, Connecticut 06410, United States
| | - Gomathinayagam Ponniah
- Product Characterization, Alexion Pharmaceuticals Inc, 352 Knotter Drive, Cheshire, Connecticut 06410, United States
| | - Nidia Gonzalez
- Product Characterization, Alexion Pharmaceuticals Inc, 352 Knotter Drive, Cheshire, Connecticut 06410, United States
| | - Dino Miano
- Product Characterization, Alexion Pharmaceuticals Inc, 352 Knotter Drive, Cheshire, Connecticut 06410, United States
| | - Hongcheng Liu
- Product Characterization, Alexion Pharmaceuticals Inc, 352 Knotter Drive, Cheshire, Connecticut 06410, United States
| |
Collapse
|
49
|
Leurs U, Mistarz UH, Rand KD. Getting to the core of protein pharmaceuticals--Comprehensive structure analysis by mass spectrometry. Eur J Pharm Biopharm 2015; 93:95-109. [PMID: 25791210 DOI: 10.1016/j.ejpb.2015.03.012] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Revised: 02/27/2015] [Accepted: 03/02/2015] [Indexed: 01/19/2023]
Abstract
Protein pharmaceuticals are the fastest growing class of novel therapeutic agents, and have been a major research and development focus in the (bio)pharmaceutical industry. Due to their large size and structural diversity, biopharmaceuticals represent a formidable challenge regarding analysis and characterization compared to traditional small molecule drugs. Any changes to the primary, secondary, tertiary or quaternary structure of a protein can potentially impact its function, efficacy and safety. The analysis and characterization of (structural) protein heterogeneity is therefore of utmost importance. Mass spectrometry has evolved as a powerful tool for the characterization of both primary and higher order structures of protein pharmaceuticals. Furthermore, the chemical and physical stability of protein drugs, as well as their pharmacokinetics are nowadays routinely determined by mass spectrometry. Here we review current techniques in primary, secondary and tertiary structure analysis of proteins by mass spectrometry. An overview of established top-down and bottom-up protein analyses will be given, and in particular the use of advanced technologies such as hydrogen/deuterium exchange mass spectrometry (HDX-MS) for higher-order structure analysis will be discussed. Modification and degradation pathways of protein drugs and their detection by mass spectrometry will be described, as well as the growing use of mass spectrometry to assist protein design and biopharmaceutical development.
Collapse
Affiliation(s)
- Ulrike Leurs
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark
| | - Ulrik H Mistarz
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark
| | - Kasper D Rand
- Department of Pharmacy, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark.
| |
Collapse
|
50
|
Takahashi O, Kirikoshi R, Manabe N. Acetic acid can catalyze succinimide formation from aspartic acid residues by a concerted bond reorganization mechanism: a computational study. Int J Mol Sci 2015; 16:1613-26. [PMID: 25588215 PMCID: PMC4307323 DOI: 10.3390/ijms16011613] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2014] [Accepted: 01/04/2015] [Indexed: 11/16/2022] Open
Abstract
Succinimide formation from aspartic acid (Asp) residues is a concern in the formulation of protein drugs. Based on density functional theory calculations using Ace-Asp-Nme (Ace = acetyl, Nme = NHMe) as a model compound, we propose the possibility that acetic acid (AA), which is often used in protein drug formulation for mildly acidic buffer solutions, catalyzes the succinimide formation from Asp residues by acting as a proton-transfer mediator. The proposed mechanism comprises two steps: cyclization (intramolecular addition) to form a gem-diol tetrahedral intermediate and dehydration of the intermediate. Both steps are catalyzed by an AA molecule, and the first step was predicted to be rate-determining. The cyclization results from a bond formation between the amide nitrogen on the C-terminal side and the side-chain carboxyl carbon, which is part of an extensive bond reorganization (formation and breaking of single bonds and the interchange of single and double bonds) occurring concertedly in a cyclic structure formed by the amide NH bond, the AA molecule and the side-chain C=O group and involving a double proton transfer. The second step also involves an AA-mediated bond reorganization. Carboxylic acids other than AA are also expected to catalyze the succinimide formation by a similar mechanism.
Collapse
Affiliation(s)
- Ohgi Takahashi
- Faculty of Pharmaceutical Sciences, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan.
| | - Ryota Kirikoshi
- Faculty of Pharmaceutical Sciences, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan.
| | - Noriyoshi Manabe
- Faculty of Pharmaceutical Sciences, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan.
| |
Collapse
|